Taltz tops Tremfya in psoriasis but data may not change prescribing habits

Eli Lilly said Taltz was superior to J&J's Tremfya in treating psoriasis at 12 weeks in the Phase IV IXORA-R trial, but the data may not move the needle on physicians’ prescribing habits.

The data add to growing evidence from head-to-head trials that suggests IL-17 inhibitors like Taltz ixekizumab could be the best bet over IL-23 inhibitors such as Tremfya guselkumab for patients wanting immediate relief. At least seven therapies across the classes are approved to treat plaque psoriasis, including Humira adalimumab successor Skyrizi risankizumab-rzaa, which AbbVie Inc. (NYSE:ABBV) launched in May (see "AbbVie's 2Q Previews Future Growth Drivers")...